Qiagen N.V.

ots Ad hoc-Service: Qiagen N.V. QIAGEN REPORTS FOURTH-QUARTER AND FISCAL 2000 YEAR-END RESULTS

Ad hoc-announcement edited and sent by DGAP. The sender is solely responsible for the contents of this announcement.

-----------------------------------------------------

    Venlo, The Netherlands (ots Ad hoc-Service) -      QIAGEN REPORTS
FOURTH-QUARTER AND FISCAL 2000 YEAR-END RESULTS

    QIAGEN N.V. (Nasdaq: QGENF, Neuer Markt: QIA, Easdaq: QGEN)
reports a successful fourth quarter and fiscal 2000 as well as
expansion of its market and technology leadership. The Company
reported that consolidated net sales for its fourth quarter increased
29% to $55.8 million, from $43.3 million for the same period in 1999.
Excluding the effect of purchased in-process research and development
costs related to the acquisition of Rapigene Inc. during the fourth
quarter of 1999, operating income for the fourth quarter 2000
increased 34% to $11.0 million from $8.2 million in the comparable
period in 1999, and net income for the quarter ended December 31,
2000 increased 10% to $6.6 million from $6.0 million in the same
quarter of 1999. Diluted earnings per share excluding the acquisition
charge increased 25% to $0.05 (based on 144.4 million average shares
and share equivalents outstanding) from $0.04 (based on 142.0 million
average shares and share equivalents outstanding) in the comparable
quarter of 1999. Excluding the costs related to the activities at
QIAGEN Genomics (formerly Rapigene Inc.) in addition to the
acquisition charges, operating income for the fourth quarter 2000
increased 55% to $12.7 million from $8.2 million in the comparable
period in 1999, net income for the fourth quarter ended December 31,
2000 increased 30% to $7.8 million from $6.0 million in the same
quarter of 1999. For fiscal 2000, net sales increased 29% to $204.0
million from $158.2 million in fiscal 1999. Operating income for the
year ended December 31, 2000 increased 50% to $34.9 million from
$23.3 million in 1999, and net income increased 45% to $20.1 million
in 2000 from $13.9 million in 1999. Diluted earnings per share for
fiscal 2000 increased 40% to $0.14 (based on 144.2 million average
shares and share equivalents) from $0.10 (based on 141.3 million
average shares and share equivalents).      

Contacts:

    QIAGEN N.V Peer M. Schatz Chief Financail Officer +49 (0)2103 29 11710 e-mail: p.schatz@de.qiagen.com

End ----------------------------------------------------- Internet: http://recherche.newsaktuell.de

Original-Content von: Qiagen N.V., übermittelt durch news aktuell

Weitere Meldungen: Qiagen N.V.

Das könnte Sie auch interessieren: